University Cancer and Blood Center, LLC - Athens Medical Oncology

Doctors:

Fredrick L. Flynt MD

Tzu-chuan Jane Huang MD

Petros G. Nikolinakos MD

Cynthia L Shepherd MD

James E. Splichal MD

Jeffrey A. Thomas MD

Clinical Trials in Georgia

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Melanoma, Unknown Primary

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Cancer Type: Breast Cancer, Unknown Primary

A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
Cancer Type: Pancreatic Cancer, Unknown Primary

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Cancer Type: Brain & Spinal Cord Tumor

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type: Multiple Myeloma

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Cancer Type: Lung Cancer

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Cancer Type: Breast Cancer

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients with Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Cancer Type: Lung Cancer

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/?or Midline Gliomas
Cancer Type: Brain Tumor

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Cancer Type: Solid Tumor, Unknown Primary

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Cancer Type: Lung Cancer

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)
Cancer Type: Breast Cancer

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type: Head and Neck Cancer, Unknown Primary

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer, Unknown Primary

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Cancer Type: Breast Cancer

Using Cancer Cells in the Blood (ctDNA) to Determine the Type of Chemotherapy that will Benefit Patients who Have Had Surgery for Colon Cancer, (CIRCULATE-NORTH AMERICA)
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy (BRAVE)
Cancer Type: Leukemia